Newsroom

Dr. Anthony Traboulsee consults a patient in the UBC Hospital MS Clinic.
Clinical trial results put liberation therapy controversy to rest Oct 30, 2018

For Dr. Anthony Traboulsee (pictured above), Director of the UBC MS & NMO Research Program at the Djavad Mowafaghian Centre for Brain Health and lead investigator on two Canada-wide clinical trials to determine the efficacy of liberation therapy in MS, it was an opportunity to listen to the community.

+
Mature woman playing a slot machine game in a casino.
Casino lights and sounds encourage risky decision-making Oct 29, 2018

Are the blinking lights and exciting jingles ubiquitous on the casino floor just a little bit of harmless ambience-building razzle dazzle, or could they affect your choices and actions when you gamble with slot machines? New research demonstrates that the sights and sounds of the casino may directly influence decision-making and behaviour, encouraging riskier choices.

+
Dr. Brianne Kent in the lab at the Djavad Mowafaghian Centre for Brain Health.
UBC postdoc takes Harvard Medical School appointment to study sleep and Alzheimer’s disease Sep 25, 2018

Pictured: Dr. Brianne Kent. Image credit: Paul Joseph/UBC.

As anyone who has ever lain awake in the dark hours after going to bed will attest, sleep is complicated and a lack of it can be disruptive to every aspect of one’s life. Deep sleep is important for a number of brain functions, and essential in clearing the brain of toxic proteins such as beta-amyloid, which can accumulate in the brain over the course of the day. Beta-amyloid proteins contribute to the plaques that form in the brain in disorders such as Alzheimer’s disease.

+
Hockey player on the bench.
New research shows athletes may be returning to the game too soon after concussion Sep 4, 2018

Detailed scans of University of British Columbia hockey players who had suffered concussions found that the protective fatty tissue surrounding brain cell fibers was loosened two weeks after the injury—even though the athletes felt fine and were deemed ready to return to the ice.

+
Researcher works at fume hood, wears headphones.
Member news: August 2018 Aug 28, 2018

Dr. Matilde Balbi (PI: Dr. Tim Murphy), Dr. Katharina Held (PI: Dr. Yu Tian Wang), Samrat Thouta (PI: Dr. Terry Snutch) recieved Research Trainee Awards from the Michael Smith Foundation for Health Research (MSFHR). 

+
Dr. Matthew Farrer at the University of British Columbia.
Genetic model offers elegant tool for testing Parkinson's disease therapies Aug 21, 2018

Pictured: Dr. Matthew Farrer. Image credit: Paul Joseph/UBC.

For the past decade, Parkinson’s disease researchers have relied on the experimental equivalent of using a sledgehammer to tune a guitar to test new therapies for the disease. This may be a reason clinical trials of promising neuroprotective drugs fail. But, in new research published today in Nature Parkinson’s Disease, researchers at the Djavad Mowafaghian Centre for Brain Health (DMCBH) may have found the ideal tool for the job.

+
Sukriti Gupta with her poster at the NeuroFutures conference.
Member news: July 2018 Jul 26, 2018

Pictured: Sukriti Gupta, an undergraduate researcher in Dr. Jeremy Seamans' lab, with her poster at NeuroFutures 2018 in Seattle. Image credit: Nate Powell.

+
Dr. Shernaz Bamji, 2018 CIHR Foundation Grant recipient.
CIHR funding for brain health, neuroplasticity research Jul 19, 2018

For the brain to function, signals need to pass between neurons in order to control movement, speech, thought, and decision-making. Each individual neuron (there are billions within a single human brain) connects to a vast and complex network of neurons through thousands of synapses. Synapses mediate communication between neurons, affecting how we perceive and react to the world around us—essentially propelling us through life and making us who we are.

+
Gene sequencing data, blue on black.
Genetic marker for drug risk in multiple sclerosis offers path toward precision medicine Jul 16, 2018

A team of researchers has uncovered a specific gene variant associated with an adverse drug reaction resulting in liver injury in a people with multiple sclerosis (MS). It is the first time researchers have been able to establish a validated genetic marker for a drug-induced harm in people with MS.

+

Pages